Daré Bioscience (NASDAQ: DARE) updates investor corporate presentation online

Rhea-AI Filing Summary

Daré Bioscience, Inc. reported that it has posted an updated corporate presentation in the Investors section of its website as of January 6, 2026. The same presentation, dated January 6, 2026, is also included as Exhibit 99.1 to this report and incorporated by reference for informational purposes. The company notes that this material is being furnished rather than filed under securities laws, which limits how it is treated for liability and incorporation into other regulatory documents. Information available on or through the company’s website, including the presentation, is not automatically incorporated into this report.

false 0001401914 0001401914 2026-01-06 2026-01-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 6, 2026

DARE BIOSCIENCE, INC.

DARÉ BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-36395		20-4139823
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

3655 Nobel Drive, Suite 260

San Diego, CA 92122

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (858) 926-7655

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock		DARE		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 6, 2026, Daré Bioscience, Inc. (“Daré” or the “Company”) made available an updated corporate presentation in the “Investors” section of its website (https://ir.darebioscience.com). A copy of the presentation, dated January 6, 2026, is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

The information in this Item 7.01 and Exhibit 99.1 to this report is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation by reference language in any such filing, except as the Company expressly sets forth by specific reference in such filing.

Information contained in, or that can be accessed through, the Company’s website or any other website referenced in its corporate presentation is not incorporated by reference into this report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Daré Bioscience corporate presentation, dated January 6, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	DARÉ BIOSCIENCE, INC.
Dated: January 6, 2026	By:	/s/ Sabrina Martucci Johnson
	Name:	Sabrina Martucci Johnson
	Title:	President and Chief Executive Officer

-3-

FAQ

What did Daré Bioscience (DARE) disclose in this report?

Daré Bioscience disclosed that it made an updated corporate presentation available on its Investors website on January 6, 2026, and furnished the same presentation as Exhibit 99.1.

Where can investors access Daré Bioscience’s updated corporate presentation?

The updated corporate presentation is available in the Investors section of Daré Bioscience’s website at https://ir.darebioscience.com, and is also attached as Exhibit 99.1.

Is the Daré Bioscience corporate presentation considered filed with the SEC?

No. The company states that the information in Item 7.01 and Exhibit 99.1 is being furnished and will not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.

Does the Daré Bioscience website information become part of this report?

No. Daré Bioscience explains that information contained in, or accessible through, its website or any other website referenced in the corporate presentation is not incorporated by reference into this report.

What exhibit did Daré Bioscience attach with this corporate presentation update?

Daré Bioscience attached Exhibit 99.1, described as the Daré Bioscience corporate presentation dated January 6, 2026, and Exhibit 104, the cover page interactive data file.

Who signed this Daré Bioscience report?

The report was signed on behalf of Daré Bioscience, Inc. by Sabrina Martucci Johnson, the company’s President and Chief Executive Officer, dated January 6, 2026.